1. Rehan F, Zhang M, Fang J, Greish K. Therapeutic applications of nanomedicine: recent developments and future perspectives. Molecules. 2024; 29(9): 2073.
2. Giri PM, Banerjee A, Layek B. A recent review on cancer nanomedicine. Cancers. 2023; 15(8): 2256.
3. Liu Q, Zou J, Chen Z, He W, Wu W. Current research trends of nanomedicines. Acta Pharm Sin B. 2023; 13(11): 4391–4416.
4. Ventola CL. The nanomedicine revolution: part 3: regulatory and safety challenges. P T. 2012; 37(11): 631.
5. He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures. Acc Chem Res. 2019; 52(9): 2445–2461.
6. Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1): 71.
7. Medicines Agency - Heads of Medicines Agencies E. Nanotechnology-based medicinal products for human use - EU-IN Horizon Scanning Report. 2025. Available from: www.ema.europa.eu
8. Atalah HN, Qansuwa EM. Worldwide development and commercialization of nanomedicine. In: Nanocarriers in neurodegenerative disorders. CRC Press; 2024; 130–139.
9. de Andrade LM, Ladeira LO. Nanomedicine as an opportunity for equity achievements through cost-reduction in public healthcare for head and neck cancer treatment in Brazil. BMC Health Serv Res. 2026; 26(1): 251.
10. Manandhar S, Sankhe R, Kumar BH, Pai KS. Clinical protocols for nanopharmacokinetics assessment. In: Nano-pharmacokinetics and theranostics. Academic Press; 2021; 193–220.
11. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017; 42(12): 742.
12. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011; 8(6): 2101–2141.
13. European Medicines Agency. Reflection paper on nanotechnology-based medicinal products for human use. EMEA/CHMP/79769/2006. EMA; 2006.
14. Penkrat V, Batra SS, Edward AE, Priyanka K, Thomas T, Medikonda P. Regulatory intelligence: a key to successful submissions. [Internet]. Available from: https://www.pharmtech.com.
15. Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arabian J Chem. 2019; 12(7): 908–931.
16. Clogston JD, Foss W, Harris D, Oberoi H, Pan J, Pu E, et al. Current state of nanomedicine drug products: an industry perspective. J Pharm Sci. 2024; 113(12): 3395–3405.
17. Ali F, Neha K, Parveen S. Current regulatory landscape of nanomaterials and nanomedicines: a global perspective. J Drug Deliv Sci Technol. 2023; 80: 104118.
18. Hertig JB, Shah VP, Flühmann B, Mühlebach S, Stemer G, Surugue J, et al. Tackling the challenges of nanomedicines: are we ready? Am J Health Syst Pharm. 2021; 78(12): 1047–1056.
19. Dri DA, Gaucci E, Torrieri I, Carafa M, Marianecci C, Gramaglia D. Critical analysis and quality assessment of nanomedicines and nanocarriers in clinical trials: three years of activity at the clinical trials office. Pharmaceutics. 2022; 14(7): 1438.
20. Salvi BV, Kantak M, Kharangate K, Trotta F, Maher T, Shende P. Blind spots in development of nanomedicines. Technol Cancer Res Treat. 2024; 23.
21. Ventola CL. The nanomedicine revolution: part 1: emerging concepts. P T. 2012; 37(9): 512–525.
22. Csóka I, Ismail R, Jójárt-Laczkovich O, Pallagi E. Regulatory considerations, challenges and risk-based approach in nanomedicine development. Curr Med Chem. 2021; 28(36): 7461–7476.
23. Rodríguez-Gómez FD, Monferrer D, Penon O, Rivera-Gil P. Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks. Front Med (Lausanne). 2025; 12.
24. Halamoda-Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer-Hoffmann S. Mapping of the available standards against the regulatory needs for nanomedicines. WIREs Nanomed Nanobiotechnol. 2019; 11(1).
25. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next-generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023; 12(30): 2301956.
26. Mühlebach S. Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?. Adv Drug Deliv Rev. 2018; 131: 122–131.
27. Sainz V, Conniot J, Matos AI, Peres C, Zupancic E, Moura L, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015; 468(3): 504–510.
28. Bleeker EA, de Jong WH, Geertsma RE, Groenewold M, Heugens EH, Koers-Jacquemijns M, et al. Considerations on the EU definition of a nanomaterial: science to support policy making. Regul Toxicol Pharmacol. 2013; 65(1): 119–125.
29. Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022; 12(3): 500–525.
30. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020; 8(17): 4653–4664.
31. Bremer-Hoffmann S, Halamoda-Kenzaoui B, Borgos SE. Identification of regulatory needs for nanomedicines. J Interdiscip Nanomed. 2018; 3(1): 4–15.
32. Bowman DM, Gatof J. Reviewing the regulatory barriers for nanomedicine: global questions and challenges. Nanomedicine. 2015; 10(21): 3275–3286.
33. Nyazema NZ, Chanyandura JT, Kumar PO. Nanomedicine and regulatory science: the challenges in Africa. Front Biomater Sci. 2023; 2: 1184662.
34. Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019; 25: 85–98.
35. Damjanovska G, Karanakov L, Georgievska KZ. Nanomedicines and off patent follow-on medicines (nanosimilars) EMA regulatory procedures overview. Maced Pharm Bull. 2023.
36. Ernst LM, Puntes V. How does immunomodulatory nanoceria work? ROS and immunometabolism. Front Immunol. 2022; 13: 750175.
37. Havelikar U, Ghorpade KB, Kumar A, Patel A, Singh M, Banjare N, et al. Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines. Discov Nano. 2024; 19(1): 165.
38. Brusini R, Varna M, Couvreur P. Advanced nanomedicines for the treatment of inflammatory diseases. Adv Drug Deliv Rev. 2020; 157: 161–178.
39. Pelaz B, Alexiou C, Alvarez-Puebla RA, Alves F, Andrews AM, Ashraf S, et al. Diverse applications of nanomedicine. ACS Nano. 2017; 11(3): 2313–2381.
40. Sim S, Wong NK. Nanotechnology and its use in imaging and drug delivery. Biomed Rep. 2021; 14(5): 42.
41. Bhardwaj V, Kaushik A, Khatib ZM, Nair M, McGoron AJ. Recalcitrant issues and new frontiers in nano-pharmacology. Front Pharmacol. 2019; 10: 1369.
42. Barenholz YC. Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2): 117–134.
43. Limaye V, Fortwengel G, Limaye D. Regulatory roadmap for nanotechnology based medicines. Int J Drug Regul Aff. 2014; 2(4): 33–41.
44. Kayyali US, Ghandakly E, Singh N, Villoutreix BO, Tsaioun K. Kinase signaling as a drug target modality for regulation of vascular hyperpermeability: a case for ARDS therapy development. Drug Discov Today. 2022; 27(5): 1448–1456.
45. Oualikene-Gonin W, Sautou V, Ezan E, Bastos H, Bellissant E, Belgodère L, et al. Regulatory assessment of nano-enabled health products in public health interest. Front Public Health. 2023; 11: 1125577.
46. Ray PC, Yu H, Fu PP. Toxicity and environmental risks of nanomaterials: challenges and future needs. J Environ Sci Health C. 2009; 27(1): 1–35.
47. Pan D. Nanomedicine and nanobiotechnology in India. WIREs Nanomed Nanobiotechnol. 2024; 16(1): e1939.
48. Devasahayam S. Nanotechnology and nanomedicine in market: a global perspective on regulatory issues. In: Characterization and biology of nanomaterials for drug delivery. Elsevier. 2019; 477–522.
49. Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014; 9: 1005–1023.
50. De Jong WH, Geertsma RE, Borchard G. Regulatory safety evaluation of nanomedical products: key issues to refine. Drug Deliv Transl Res. 2022; 12(9): 2042–2047.
51. Halappanavar S, van den Brule S, Nymark P, Haase A, Jarvis I, Wallin H, et al. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale. Part Fibre Toxicol. 2019; 16(1): 41.
52. Wasti S, Lee IH, Kim S, Lee JH, Kim H. Ethical and legal challenges in nanomedical innovations: a scoping review. Front Genet. 2023; 14: 1163392.
53. Gujjar S, Kukal S, Jayabal P, Balaji N, Sainger S, Roy S, et al. Nanomaterials for biomedical applications: addressing regulatory hurdles and strategic solutions. Nano Trends. 2025; 100127.
54. Marchant GE, Sylvester DJ. Transnational models for regulation of nanotechnology. J Law Med Ethics. 2006; 34(4): 714–725.
55. Tripathi D, Pandey P, Sharma S, Rai AK, BH MP. Advances in nanomaterials for precision drug delivery: insights into pharmacokinetics and toxicity. BioImpacts. 2024; 15: 30573.
56. FDA NanoDay Symposium 2022. US Food and Drug Administration; 2022 [cited 2025 Oct 5]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-nanoday-symposium-2022-10112022.
57. Furxhi I, Costa A, Vázquez-Campos S, Fito-López C, Hristozov D, Ramos JA, et al. Status, implications and challenges of European safe and sustainable by design paradigms applicable to nanomaterials and advanced materials. RSC Sustain. 2023; 1(2): 234–250.
58. Desai N, Rana D, Patel M, Bajwa N, Prasad R, Vora LK. Nanoparticle therapeutics in clinical perspective: classification, marketed products, and regulatory landscape. Small. 2025.
59. Ruiz-González N, Esporrín-Ubieto D, Kim ID, Wang J, Sánchez S. Micro- and nanomotors: engineered tools for targeted and efficient biomedicine. ACS Nano. 2025; 19(9): 8411–8432.
60. Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, et al. Regulatory insights into nanomedicine and gene vaccine innovation: safety assessment, challenges, and regulatory perspectives. Acta Biomater. 2024; 180: 1–17.
61. Zhang X, Chan HW, Shao Z, Wang Q, Chow S, Chow SF. Navigating translational research in nanomedicine: a strategic guide to formulation and manufacturing. Int J Pharm. 2025; 671: 125202.
62. Omidian H, Cubeddu LX, Wilson RL. Peptide-functionalized nanomedicine: advancements in drug delivery, diagnostics, and biomedical applications. Molecules. 2025; 30(7): 1572.
63. Abram SL, Tavernaro I, Johnston LJ, Zou S, Resch-Genger U. Nanoscale reference and test materials for the validation of characterization methods for engineered nanomaterials — current state, limitations, and needs. Anal Bioanal Chem. 2025; 417(12): 2405–2425.
64. Chow JCL. Monte Carlo simulations in nanomedicine: advancing cancer imaging and therapy. Nanomaterials. 2025; 15(2): 117.
65. Fadeel B, Garcia-Bennett AE. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev. 2010; 62(3): 362–374.
66. Fisher E. Lessons learned from the Ethical, Legal and Social Implications program (ELSI): planning societal implications research for the National Nanotechnology Program. Technol Soc. 2005; 27(3): 321–328.
67. Caputo F, Favre G, Borchard G, Calzolai L, Fisicaro P, Frejafon E, et al. Toward an international standardisation roadmap for nanomedicine. Drug Deliv Transl Res. 2024; 14(9): 2578–2588.
68. Fornaguera C, García-Celma MJ. Personalized nanomedicine: a revolution at the nanoscale. J Pers Med. 2017; 7(4): 12.
69. Acebes-Fernández V, Landeira-Viñuela A, Juanes-Velasco P, Hernández AP, Otazo-Perez A, Manzano-Román R, et al. Nanomedicine and onco-immunotherapy: from the bench to bedside to biomarkers. Nanomaterials. 2020; 10(7): 1274.
70. Singh AV, Rosenkranz D, Ansari MH, Singh R, Kanase A, Singh SP, et al. Artificial intelligence and machine learning empower advanced biomedical material design to toxicity prediction. Adv Intell Syst. 2020; 2(12): 2000084.
71. DiFrancesco J. The FDA’s draft guidance: use of AI in regulatory decision-making for drug and biological products. [Internet]. Available from: https://www.thefdalawblog.com.
72. Pinheiro LC, Arlett P, Roes K, Tshinanu FM, Westman G, Frias Z, et al. Artificial intelligence in European medicines regulation: from vision to action. Clin Pharmacol Ther. 2024; 117(2): 335.
73. Pitts PJ. Towards meaningful engagement for the patient voice. Patient. 2019; 12(4): 361–363.
74. Hartung T, Whelan M, Tong W, Califf RM. Is regulatory science ready for artificial intelligence?. NPJ Digit Med. 2025; 8(1).
75. Ouicher C. The regulatory intelligence in the pharmaceutical industry. STP Pharma Pratiques. 2008; 18(3): 259.
76. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006; 24(10): 1211–1217.
77. Chiu K, Racz R, Burkhart K, Florian J, Ford K, Iveth Garcia M, et al. New science, drug regulation, and emergent public health issues: the work of FDA's division of applied regulatory science. Front Med. 2023; 9: 1109541.
78. Pignatti F, Gravanis I, Herold R, Vamvakas S, Jonsson B, Marty M. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation. Clin Cancer Res. 2011; 17(16): 5220–5225.
79. Kim J, Hur M, Min M. From RAG to QA-RAG: integrating generative AI for pharmaceutical regulatory compliance process. In: Proceedings of the 40th ACM/SIGAPP Symposium on Applied Computing; 2025; 1293–1295.
80. Fu L, Jia G, Liu Z, Pang X, Cui Y. The applications and advances of artificial intelligence in drug regulation: a global perspective. Acta Pharm Sin B. 2025; 15: 1–14.
81. Coty JB, Vauthier C. Characterization of nanomedicines: a reflection on a field under construction needed for clinical translation success. J Control Release. 2018; 275: 254–268.
82. Zhang X, Centurion F, Misra A, Patel S, Gu Z. Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment. Adv Drug Deliv Rev. 2023; 194: 114709.
83. de la Torre BG, Albericio F. The pharmaceutical industry in 2019. An analysis of FDA drug approvals from the perspective of molecules. Molecules. 2020; 25(3): 745.
84. Norsworthy KJ, Lee-Alonzo RJ, Pazdur R. FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit. Nat Rev Clin Oncol. 2024; 21(5): 333–334.
85. Gao X, Lowry GV. Progress towards standardized and validated characterizations for measuring physicochemical properties of manufactured nanomaterials relevant to nano health and safety risks. NanoImpact. 2018; 9: 14–30.
86. Miernicki M, Hofmann T, Eisenberger I, von der Kammer F, Praetorius A. Legal and practical challenges in classifying nanomaterials according to regulatory definitions. Nat Nanotechnol. 2019; 14(3): 208–216.
87. Murugappan MN, King-Kallimanis BL, Bhatnagar V, Kanapuru B, Farley JF, Seifert RD, et al. Patient-reported frailty phenotype (PRFP) vs. international myeloma working group frailty index (IMWG FI) proxy: a comparison between two approaches to measuring frailty. J Geriatr Oncol. 2024; 15(2): 101681.
88. Huang H, Feng W, Chen Y, Shi J. Inorganic nanoparticles in clinical trials and translations. Nano Today. 2020; 35.
89. Schmutz M, Borges O, Jesus S, Borchard G, Perale G, Zinn M, et al. A methodological safe-by-design approach for the development of nanomedicines. Front Bioeng Biotechnol. 2020; 8: 258.
90. Wang Y, Grainger DW. Regulatory considerations specific to liposome drug development as complex drug products. Front Drug Deliv. 2022; 2: 901281.
91. Rijcken CJ. The translational journey of cancer nanomedicines: biological and entrepreneurial lessons learned. Drug Deliv Transl Res. 2025: 1–2.
92. Rujido-Santos I, del Castillo Busto ME, Abad-Alvaro I, Herbello-Hermelo P, Bermejo-Barrera P, Barciela-Alonso MC, et al. spICP-MS characterisation of released silver nanoparticles from (nano) textile products. Spectrochim Acta B. 2022; 195: 106505.
93. McKelvey BA, Garrett-Mayer E, Rivera DR, Alabaster A, Andrews HS, Bond EG, et al. Evaluation of real-world tumor response derived from electronic health record data sources: a feasibility analysis in patients with metastatic non-small cell lung cancer treated with chemotherapy. JCO Clin Cancer Inform. 2024; 8: e2400091.
94. Seymour EM, Azevedo A, Wright JK, Reisdorph BR, Moore M, Weatherwax KJ. Electronic submission capability to FDA for academic investigators — the process, challenges, and opportunities affecting the translational research enterprise. Clin Transl Sci. 2013; 7(1): 63.
95. Siebert M, Caquelin L, Naudet F, Ross JS, Ramachandran R. Evidence supporting European Medicines Agency drug approvals (2020–2023): a cross-sectional study of trial design and outcomes. Clin Trials. 2026.
96. US Food and Drug Administration. Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation. Guidance for Industry (CDER). 2018.
97. Caputo F, Clogston J, Calzolai L, Rösslein M, Prina-Mello A. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL: a step-by-step approach combining orthogonal measurements. J Control Release. 2019; 299: 31–43.
98. Sainz V, Conniot J, Matos AI, Peres C, Zupancic E, Moura L, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015; 468(3): 504–510.
99. Rüger J, Ioannou S, Castanotto D, Stein CA. Oligonucleotides to the (gene) rescue: FDA approvals 2017–2019. Trends Pharmacol Sci. 2020; 41(1): 27–41.
100. Almazyad AF, Haq N, Alsarra IA, Alshehri S, Alam P, Imran M, et al. Novel drug delivery systems approved by USFDA from 2019 to 2023: a comprehensive review. Curr Drug Deliv. 2025.
101. Watson T. A global perspective on compassionate use and expanded access. Ther Innov Regul Sci. 2017; 51(2): 143–145.
102. Walsh J, Penazzato M, Scott C, Casas CP. Innovative delivery systems for paediatric medicines: technology landscape. World Health Organization; 2021.
103. Nikitina J. Press releases of COVID-19 vaccine manufacturers. In: Persuasion in specialized discourse: a multidisciplinary perspective. 2024;22: 92.
104. Rahman M, Beg S, Alharbi KS, Alruwaili NK, Alotaibi NH, Alzarea AI, et al. Implications of solid lipid nanoparticles of ganoderic acid for the treatment and management of hepatocellular carcinoma. J Pharm Innov. 2021; 16(2): 359–370.
105. Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz Y, et al. Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci. 2014; 1313(1): 35–56.
106. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013; 9(1): 1–14.
107. Bhatia P, Chugh A. A multilevel governance framework for regulation of nanomedicine in India. Nanotechnol Rev. 2017; 6(4): 373–382.
108. Mangla B, Kumar P, Javed S, Pathan T, Ahsan W, Aggarwal G. Regulating nanomedicines: challenges, opportunities, and the path forward. Nanomedicine. 2025; 20(15): 1911–1927.
109. Kandukuri A, Edla DR. Ensuring data safety: pharmacovigilance processes, ADR reporting, regulatory bodies, and software solutions. Asian J Pharm Res Dev. 2025; 13(3): 40–47.
110. Satalkar P, Elger BS, Hunziker P, Shaw D. Challenges of clinical translation in nanomedicine: a qualitative study. Nanomedicine. 2016; 12(4): 893–900.
111. Malik R, Patil S. Nanotechnology: regulatory outlook on nanomaterials and nanomedicines in United States, Europe and India. Appl Clin Res Clin Trials Regul Aff. 2020; 7(3): 225–236.
112. Kurul F, Turkmen H, Cetin AE, Topkaya SN. Nanomedicine: how nanomaterials are transforming drug delivery, bio-imaging, and diagnosis. Next Nanotechnol. 2025; 7: 100129.
113. Bleeker EA, Swart E, Braakhuis H, Cruz ML, Friedrichs S, Gosens I, et al. Towards harmonisation of testing of nanomaterials for EU regulatory requirements on chemical safety — a proposal for further actions. Regul Toxicol Pharmacol. 2023; 139: 105360.
114. Mahmoudi M. The need for robust characterization of nanomaterials for nanomedicine applications. Nat Commun. 2021; 12(1): 5246.
115. Singh A. Role of regulatory affairs in nanoparticles formulation. Pharmaspire. 2023; 15(4): 211–217.
116. Yasri S, Wiwanitkit V. Important ethical issues for nanomedicine. J Res Med Sci. 2017; 22(1): 138.
117. Choi K. Public engagement and education for ethics in nanotechnology. In: Nanotechnologies, ethics, and politics. 2007: 181–204.
118. Marchant GE, Sylvester DJ, Abbott KW, Danforth TL. International harmonization of regulation of nanomedicine. Stud Ethics Law Tech. 2009; 3: 1.
119. Venugopal SM. Large language models-powered agentic AI design and implementation in pharmacovigilance — a narrative review. J Med Artif Intell. 2026; 9.
120. Butler D, Vucic K, Straus S, Cupelli A, Micallef B, Serracino-Inglott A, et al. Regulatory experience of handling risk management plans (RMPs) for medicinal products in the EU. Expert Opin Drug Saf. 2021; 20(7): 815–826.
121. Tran L, Bañares MA, Rallo R. Modelling the toxicity of nanoparticles. Springer International Publishing; 2017.
122. Mehta J, Pathania K, Pawar SV. Recent overview of nanotechnology based approaches for targeted delivery of nutraceuticals. Sustain Food Technol. 2025; 3(4): 947–978.
123. Feitshans I. Law and policy of nanotechnology in food: global commerce promoting global health from field to fork. Geo L Tech Rev. 2025; 9: 121.
124. Desai MK. Artificial intelligence in pharmacovigilance — opportunities and challenges. Perspect Clin Res. 2024; 15(3): 116–121.
125. Thornton O. The reflexive scholar: a meta-analysis and strategic proposal for personal citation intelligence systems. [Internet]. 2025.
126. Sawant R, Kumar S. Collaboration among industry, academia, and government to fuel innovative drug discovery research. J Med Chem. 2025; 68(23): 24725–24729.
127. Bawa R, Barenholz Y, Owen A. In: Braddock M, editor. Nanomedicines: design, delivery and detection. The Royal Society of Chemistry; 2016; 51: 290–314.
128. Lustig TA, Weisfeld V, editors. International regulatory harmonization amid globalization of drug development: workshop summary. National Academies Press; 2013.
129. Bhatia P, Vasaikar S, Wali A. A landscape of nanomedicine innovations in India. Nanotechnol Rev. 2018; 7(2): 131–148.
130. Malik S, Muhammad K, Waheed Y. Emerging applications of nanotechnology in healthcare and medicine. Molecules. 2023; 28(18): 6624.
131. Fadeel B, Farcal L, Hardy B, Vázquez-Campos S, Hristozov D, Marcomini A, et al. Advanced tools for the safety assessment of nanomaterials. Nat Nanotechnol. 2018; 13(7): 537–543.
